Health & Pharma
Bayer's First-Ever Factor XIa Drug Rebuilds a Shrunken Blockbuster Bet
The FDA cleared Bayer's Sunharbo as the first factor XIa inhibitor, but peak sales hopes sit above €1 billion, far below the original €5 billion thesis, with a $9,100 annual list price and a BMS/J&J rival closing in.
- CVS Is Unwinding the Deal That Built It
- J&J's Rybrevant Wins the First New Second-Line Head and Neck Cancer Drug in a Decade
- FDA Approves the First DNA-Based Immunotherapy, on a 32-Patient Trial
- A Catholic Nonprofit Is Taking Surgery Partners Private
- Hepatitis B's First Functional Cure Reaches the US Market
- AstraZeneca's Ultomiris Cuts IgAN Proteinuria 43%, but the Kidney Proof Is Still Pending
- GSK's New Drug Could Spare Rectal Cancer Patients Surgery
- Spire’s £1.03 Billion Takeover Shifts the Hospital Cost Test to Private Capital



















































